Last reviewed · How we verify
Pegylated Lyposomal Doxorubicin
At a glance
| Generic name | Pegylated Lyposomal Doxorubicin |
|---|---|
| Also known as | SCH 200746 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) (PHASE2)
- Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) (PHASE4)
- Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated Lyposomal Doxorubicin CI brief — competitive landscape report
- Pegylated Lyposomal Doxorubicin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI